Vaccination Against Varicella and Zoster: Its Development and Progress

  • Anne Gershon


At one time in history, it seems, rash diseases tended to be lumped together under the term “pox” and these illnesses must have been very common. Syphilis was known as the “great pox” and smallpox was considered yet another “pox” illness. The well known quotation from Shakespeare’s play, Romeo and Juliet, is usually given as “A pox on both your houses.” In fact however, “A plague on both your houses” is what Shakespeare actually wrote; plague killed 25% of the European population between 1347 and 1348. “Pox” diseases included plague perhaps, as well as smallpox, syphilis, measles, rubella, chickenpox, and more. Eventually, scientific advances would considerably delineate the diversity of the myriad of pathogens that cause human infections manifested by fever and rash.


Necrotizing Fasciitis Leukemic Child Varicella Vaccine Varicella Vaccination Immunocompromised Child 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Cohen, J.I., S.E. Straus, and A. Arvin, Varicella-Zoster Virus: Replication, Pathogenesis, and Management, in Fields Virology, D.M. Knipe and P.M. Howley, Editors. 2007, Lippincott Williams and Wilkins: Philadelphia. p. 2773–2818.Google Scholar
  2. 2.
    Gershon, A., M. Takahashi, and J. Seward, Live attenuated varicella vaccine, in Vaccines, S. Plotkin, W. Orenstein, and P. Offit, Editors. 2008, WB Saunders: Philadelphia. p. 915–958.Google Scholar
  3. 3.
    Garland, J., Varicella following exposure to herpes zoster. N. Engl. J. Med., 1943. 228: p. 336–337.CrossRefGoogle Scholar
  4. 4.
    Hayakawa, Y., et al., Analysis of varicella zoster virus (VZV) DNAs of clinical isolates by endonuclease HpaI. J. Gen. Virol., 1986. 67: p. 1817–1829.PubMedCrossRefGoogle Scholar
  5. 5.
    Straus, S.E., et al., Endonuclease analysis of viral DNA from varicella and subsequent zoster infections in the same patient. N. Engl. J. Med., 1984. 311: p. 1362–1364.PubMedCrossRefGoogle Scholar
  6. 6.
    Williams, D.L., et al., Herpes zoster following varicella vaccine in a child with acute lymphocytic leukemia. J. Pediatr., 1985. 106: p. 259–261.PubMedCrossRefGoogle Scholar
  7. 7.
    Weller, T.H. and A.H. Coons, Fluorescent antibody studies with agents of varicella and herpes zoster propagated in vitro. Proc Soc Exp Biol Med, 1954. 86(4): p. 789–94.PubMedGoogle Scholar
  8. 8.
    Cook, M.L. and J. Stevens, Labile coat: reason for noninfectious cell-free varicella zoster virus in culture. J Virol, 1968. 2: p. 1458–1464.PubMedGoogle Scholar
  9. 9.
    Chen, J.J., et al., Mannose 6-phosphate receptor dependence of varicella zoster virus infection in vitro and in the epidermis during varicella and zoster. Cell, 2004. 119(7): p. 915–926.PubMedCrossRefGoogle Scholar
  10. 10.
    Brunell, P.A., Transmission of chickenpox in a school setting prior to the observed exanthem. Amer J Dis Child, 1989. 143: p. 1451–1452.PubMedGoogle Scholar
  11. 11.
    Ku, C.C., et al., Tropism of Varicella-Zoster Virus for Human Tonsillar CD4(+) T Lymphocytes That Express Activation, Memory, and Skin Homing Markers. J Virol, 2002. 76(22): p. 11425–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Guess, H.A., et al., Population-based studies of varicella complications. Pediatrics, 1986. 78(4 Pt 2): p. 723–7.PubMedGoogle Scholar
  13. 13.
    Ku, C.C., et al., Varicella-Zoster Virus Transfer to Skin by T Cells and Modulation of Viral Replication by Epidermal Cell Interferon-{alpha}. J Exp Med, 2004. 200(7): p. 917–925.PubMedCrossRefGoogle Scholar
  14. 14.
    Ku, C.C., et al., Varicella-Zoster virus pathogenesis and immunobiology: new concepts emerging from investigations with the SCIDhu mouse model. J Virol, 2005. 79(5): p. 2651–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Ross, A.H., E. Lencher, and G. Reitman, Modification of chickenpox in family contacts by administration of gamma globulin. N. Engl. J. Med., 1962. 267: p. 369–376.PubMedCrossRefGoogle Scholar
  16. 16.
    Brunell, P. and H. Casey, Crude tissue culture antigen for determination of varicella-zoster complement fixing antibody. Publ Heal Rep, 1964. 79: p. 839–841.Google Scholar
  17. 17.
    Demmler, G., et al., Rapid enzyme-linked immunosorbent assay for detecting antibody to varicella-zoster virus. J. Infect. Dis., 1988. 157: p. 211–212.PubMedCrossRefGoogle Scholar
  18. 18.
    Williams, V., A. Gershon, and P. Brunell, Serologic response to varicella-zoster membrane antigens measured by indirect immunofluorescence. J. Infect. Dis., 1974. 130: p. 669–672.PubMedCrossRefGoogle Scholar
  19. 19.
    Michalik, D.E., et al., Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis, 2008. 197(7): p. 944–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Rand, K.H., et al., Cellular immunity and herpesvirus infections in cardiac transplant patients. N Engl J Med, 1977. 296: p. 1372–1377.PubMedCrossRefGoogle Scholar
  21. 21.
    Berger, R., G. Florent, and M. Just, Decrease of the lympho-proliferative response to varicella-zoster virus antigen in the aged. Infect. Imm., 1981. 32: p. 24–27.Google Scholar
  22. 22.
    Burke, B.L., et al., Immune responses to varicella-zoster in the aged. Arch. Intern. Med., 1982. 142: p. 291–293.PubMedCrossRefGoogle Scholar
  23. 23.
    Takahashi, M., et al., Live vaccine used to prevent the spread of varicella in children in ­hospital. Lancet, 1974. 2: p. 1288–1290.PubMedCrossRefGoogle Scholar
  24. 24.
    Takahashi, M., et al., Development of varicella vaccine. J Infect Dis, 2008. 197 Suppl 2: p. S41–4.PubMedCrossRefGoogle Scholar
  25. 25.
    Arbeter, A.M., et al., Live attenuated varicella vaccine: the KMcC strain in healthy children. Pediatrics, 1983. 71: p. 307–312.PubMedGoogle Scholar
  26. 26.
    Neff, B.J., et al., Clinical and laboratory studies of KMcC strain of live attenuated varicella virus. Proc Soc Exp Biol Med, 1981. 166: p. 339–347.PubMedGoogle Scholar
  27. 27.
    Takahashi, M., et al., Development of a live attenuated varicella vaccine. Biken J, 1975. 18: p. 25–33.PubMedGoogle Scholar
  28. 28.
    Takahashi, M., et al., Active immunization for varicella zoster virus, in The Human Herpesviruses, A.J. Nahmais, W.R. Dowdle, and R.E. Schnazi, Editors. 1981, Elsevier: New York. p. 414–431.Google Scholar
  29. 29.
    Takahashi, M., et al., Active immunization for varicella-zoster virus, in The Human Herpesviruses, A.J. Nahmias, W.R. Dowdle, and R.E. Schinazi, Editors. 1984, Elsevier: New York. p. 255.Google Scholar
  30. 30.
    Takahashi, M. and K. Baba, A live varicella vaccine: its protective effect and immunological aspects of varicella-zoster virus infection, in Medical Virology, L. de al Maza and E.M. Peterson, Editors. 1984, Elsevier: New York. p. 255.Google Scholar
  31. 31.
    Brunell, P.A., Varicella vaccine: the crossroads is where we are not! Pediatrics, 1978. 62(5): p. 858–9.PubMedGoogle Scholar
  32. 32.
    Gelb, L.D., et al., Molecular epidemiology of live, attenuated varicella virus vaccine in children and in normal adults. J Infect Dis, 1987. 155: p. 633–640.PubMedCrossRefGoogle Scholar
  33. 33.
    Gershon, A.A., et al., Live attenuated varicella vaccine: efficacy for children with leukemia in remission. J.A.M.A., 1984. 252: p. 355–362.PubMedCrossRefGoogle Scholar
  34. 34.
    LaRussa, P., et al., Restriction fragment length polymorphism of polymerase chain reaction products from vaccine and wild-type varicella-zoster virus isolates. J. Virol., 1992. 66: p. 1016–1020.PubMedGoogle Scholar
  35. 35.
    Loparev, V.N., et al., Improved identification and differentiation of varicella-zoster virus (VZV) wild type strains and an attenuated varicella vaccine strain using a VZV open reading frame 62-based PCR. J. Clin. Micro., 2000. 38: p. 3156–3160.Google Scholar
  36. 36.
    Loparev, V.N., et al., Rapid genotyping of varicella-zoster virus vaccine and wild type strains with fluorophore-labeled hybridization probes. J. Clin. Micro., 2000. 38: p. 4315–4319.Google Scholar
  37. 37.
    Loparev, V.N., Rubtcova, E., Seward, J.F., Levin, M.J., Schmid, D.S., DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine. J Infect Dis, 2007. 196: p. 801–2.Google Scholar
  38. 38.
    Lopez, A.S., et al., Transmission of a Newly Characterized Strain of Varicella-Zoster Virus from a Patient with Herpes Zoster in a Long-Term-Care Facility, West Virginia, 2004. J Infect Dis, 2008. 197(5): p. 646–653.PubMedCrossRefGoogle Scholar
  39. 39.
    Quinlivan, M.L., et al., Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts. Proc Natl Acad Sci U S A, 2007. 104(1): p. 208–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Feldman, S. and L. Lott, Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics, 1987. 80: p. 465–472.PubMedGoogle Scholar
  41. 41.
    Mitus, A., et al., Attenuated measles vaccine in children with acute leukemia. Am J Dis Child, 1962. 103: p. 413–8.PubMedGoogle Scholar
  42. 42.
    Izawa, T., et al., Application of a live varicella vaccine in children with acute leukemia or other malignant diseases. Pediatrics, 1977. 60: p. 805–809.PubMedGoogle Scholar
  43. 43.
    Arbeter, A., et al., Immunization of children with acute lymphoblastic leukemia with live attenuated varicella vaccine without complete suspension of chemotherapy. Pediatrics, 1990. 85: p. 338–344.PubMedGoogle Scholar
  44. 44.
    Brunell, P.A., et al., Administration of live varicella vaccine to children with leukemia. Lancet, 1982. 2: p. 1069–1073.PubMedCrossRefGoogle Scholar
  45. 45.
    Gershon, A., P. LaRussa, and S. Steinberg, Varicella vaccine: use in immunocompromised patients, in Infectious Disease Clinics of North America, R.E. J. White, Editor. 1996, Saunders: Philadelphia. p. 583–594.Google Scholar
  46. 46.
    Krugman, S., J.P. Giles, and J. Hammond, Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA, 1967. 200(5): p. 365–73.PubMedCrossRefGoogle Scholar
  47. 47.
    Szmuness, W., et al., Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med, 1980. 303(15): p. 833–41.PubMedCrossRefGoogle Scholar
  48. 48.
    Centers-for-Disease-Control, Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR, 2007. 56: p. 1–40.Google Scholar
  49. 49.
    Ampofo, K., et al., Persistence of immunity to live attenuated varicella vaccine in healthy adults. Clin Infect Dis, 2002. 34(6): p. 774–9.PubMedCrossRefGoogle Scholar
  50. 50.
    Gershon, A.A., S. Steinberg, and NIAID-Collaborative-Varicella-Vaccine-Study-Group., Live attenuated varicella vaccine: protection in healthy adults in comparison to leukemic children. J. Infect. Dis., 1990. 161: p. 661–666.PubMedCrossRefGoogle Scholar
  51. 51.
    Weibel, R., et al., Live attenuated varicella virus vaccine: efficacy trial in healthy children. N Engl J Med, 1984. 310: p. 1409–1415.PubMedCrossRefGoogle Scholar
  52. 52.
    Vazquez, M., et al., The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med., 2001. 344: p. 955–960.PubMedCrossRefGoogle Scholar
  53. 53.
    Vazquez, M., et al., Effectiveness over time of varicella vaccine. JAMA, 2004. 291(7): p. 851–5.PubMedCrossRefGoogle Scholar
  54. 54.
    Kamiya, H., et al., Immunization of acute leukemic children with a live varicella vaccine (Oka strain). Biken J, 1984. 27: p. 99–102.PubMedGoogle Scholar
  55. 55.
    Broyer, M. and B. Boudailliez, Prevention of varicella infection in renal transplanted children by previous immunization with a live attenuated varicella vaccine. Transpl Proc, 1985. 17: p. 151–152.Google Scholar
  56. 56.
    Broyer, M., et al., Varicella and zoster in children after kidney transplantation: long term results of vaccination. Pediatrics, 1997. 99: p. 35–39.PubMedCrossRefGoogle Scholar
  57. 57.
    Hardy, I.B., et al., The incidence of zoster after immunization with live attenuated varicella vaccine. A study in children with leukemia. N. Engl. J. Med., 1991. 325: p. 1545–1550.PubMedCrossRefGoogle Scholar
  58. 58.
    Hayakawa, Y., et al., Biologic and biophysical markers of a live varicella vaccine strain (Oka): identification of clinical isolates from vaccine recipients. J. Infect. Dis., 1984. 149: p. 956–963.PubMedCrossRefGoogle Scholar
  59. 59.
    Son, M., et al., Vaccination of Children with Perinatal HIV Infection Protects against Varicella and Zoster, in Pediatric Academic Societies Annual Meeting. 2008: Honolulu.Google Scholar
  60. 60.
    Chen, J., et al., Latent and lytic infection of isolated guinea pig enteric and dorsal root ganglia by varicella zoster virus. J. Med. Virol., 2003. 70: p. S71–78.PubMedCrossRefGoogle Scholar
  61. 61.
    Gershon, A.A., J. Chen, and M.D. Gershon, A model of lytic, latent, and reactivating varicella-zoster virus infections in isolated enteric neurons. J Infect Dis, 2008. 197 Suppl 2: p. S61–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Rentier, B., et al. Varicella-zoster virus latency in the nervous system of rats and humans is accompanied by the abundant expression of an immediate-early protein that is also present in acute infection. in Keystone Symposium on Virus entry, replication, and pathogenesis. 1996. Santa Fe.Google Scholar
  63. 63.
    Head, H. and C. A.W., The pathology of herpes zoster and its bearing on sensory localization. Brain, 1900. 23: p. 353–523.CrossRefGoogle Scholar
  64. 64.
    Seiler, H.E., A study of herpes zoster particularly in its relationship to chickenpox. J Hyg (Lond), 1949. 47(3): p. 253–62.CrossRefGoogle Scholar
  65. 65.
    Seward, J., et al. Decline of varicella disease: evidence of vaccine impact. in Society for Pediatric Research. 2000. Boston.Google Scholar
  66. 66.
    Seward, J.F., et al., Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA, 2002. 287(5): p. 606–11.PubMedCrossRefGoogle Scholar
  67. 67.
    Seward, J.F. and W.A. Orenstein, Commentary: the case for universal varicella immunization. Pediatr Infect Dis J, 2006. 25(1): p. 45–6.PubMedGoogle Scholar
  68. 68.
    Nguyen, H.Q., A.O. Jumaan, and J.F. Seward, Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med, 2005. 352(5): p. 450–8.PubMedCrossRefGoogle Scholar
  69. 69.
    Yih, W.K., et al., The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health, 2005. 5(1): p. 68.PubMedCrossRefGoogle Scholar
  70. 70.
    Zhou, F., et al., Impact of varicella vaccination on health care utilization. JAMA, 2005. 294(7): p. 797–802.PubMedCrossRefGoogle Scholar
  71. 71.
    Centers-for-Disease-Control, Prevention of Varicella. Morb. Mort. Wkly. Rep., 2007. 56: p. 1–55.Google Scholar
  72. 72.
    Berger, R., D. Luescher, and M. Just, Enhancement of varicella-zoster-specific immune responses in the elderly by boosting with varicella vaccine. J Infect Dis, 1984. 149: p. 647.PubMedCrossRefGoogle Scholar
  73. 73.
    Levin, M.J., Use of varicella vaccines to prevent herpes zoster in older individuals. Arch Virol Suppl, 2001. 17: p. 151–60.PubMedGoogle Scholar
  74. 74.
    Oxman, M.N., et al., A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med, 2005. 352(22): p. 2271–84.PubMedCrossRefGoogle Scholar
  75. 75.
    Gershon, A., et al., The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis., 1996. 173: p. 450–453.PubMedCrossRefGoogle Scholar
  76. 76.
    Wood, S.M., et al., Primary Varicella and Herpes Zoster Among HIV-Infected Children From 1989 to 2006. Pediatrics, 2008. 121(1): p. e150-e156.PubMedCrossRefGoogle Scholar
  77. 77.
    Edmunds, W.J. and M. Brisson, The effect of vaccination on the epidemiology of varicella zoster virus. J Infect, 2002. 44(4): p. 211–9.PubMedCrossRefGoogle Scholar
  78. 78.
    Insinga, R.P., et al., The incidence of herpes zoster in a United States administrative database. J Gen Intern Med, 2005. 20(8): p. 748–53.PubMedCrossRefGoogle Scholar
  79. 79.
    Jumaan, A.O., et al., Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992–2002. J Infect Dis, 2005. 191(12): p. 2002–7.PubMedCrossRefGoogle Scholar
  80. 80.
    Leung, J., N. Molinari, and R. Harpaz. Trends in the incidence of herpes zoster using a National Insurance Database: United States 1993–2003. in 43rd Annual Infectious Disease Society of America Meeting. 2005. San Francisco.Google Scholar
  81. 81.
    Mullooly, J.P., et al., Incidence of herpes zoster, 1997–2002. Epidemiol Infect, 2005. 133(2): p. 245–53.PubMedCrossRefGoogle Scholar
  82. 82.
    Brisson, M., et al., Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect, 2001. 127(2): p. 305–14.PubMedCrossRefGoogle Scholar
  83. 83.
    Ragozzino, M.E., et al., Population-based study of herpes zoster and its sequelae. Medicine, 1982. 61: p. 310–316.PubMedCrossRefGoogle Scholar
  84. 84.
    Centers-for-Disease-Control, Update: Recommendations from the Advisory Committee on Immunization Practices (ACIP) Regarding Administration of Combination MMRV Vaccine. MMWR, 2008. 57: p. 258–260.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of PediatricsColumbia UniversityNew YorkUSA

Personalised recommendations